Barclays’s Neurogene NGNE Stock Holding History

Barclays’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-60	Closed	-$3K	–	7296
2018 Q2	$3K	Buy	+60	New	+$15.6K	﹤0.01%	6785

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Barclays's NGNE Position: Q1 2026 in Review

Barclays reduced its Neurogene (NGNE) stake by 82% in Q1 2026, selling an estimated $245K and leaving 2,751 shares worth $55.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4279.

Barclays first reported a position in NGNE in Q4 2015 and has held it in 26 quarters since. The position peaked at $861K in Q1 2022. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

Barclays held 2,751 shares of Neurogene worth $55.5K as of Q1 2026.
Barclays sold 12,624 Neurogene shares in Q1 2026, an estimated $245K.
Neurogene made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4279 holding.
Barclays first reported a position in Neurogene in Q4 2015 and has held it in 26 quarters since.
Barclays's Neurogene position peaked at $861K in Q1 2022.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.